The partners will use Anima’s mRNA Lightning platform to discover novel mRNA biology modulators for the collaboration targets, with AbbVie gaining exclusive rights to licence, further develop and commercialise the resulting programmes.
In exchange, an upfront payment of $42m will be given to Anima, which may be eligible to receive up to $540m in option fees and research and development milestones in total for the three targets, with the potential for further commercial milestones as well as tiered royalties on net sales.
